Verge Genomics and Eli Lilly Achieve Milestones in AI-Driven ALS Drug Discovery Collaboration

AI-Powered Platform Demonstrates High Success in ALS Target Identification

Verge Genomics, a clinical-stage biotechnology company, has announced significant milestones in its collaboration with Eli Lilly to discover and develop novel treatments for amyotrophic lateral sclerosis (ALS). The partnership, initiated in July 2021, has leveraged Verge's AI-enabled CONVERGE platform to identify and validate drug targets for ALS with remarkable efficiency 1

1

2

2

.

Impressive Validation Rates Surpass Industry Standards

The CONVERGE platform has demonstrated robust predictive power, with 83% of prioritized targets being validated in disease-relevant models. This success rate significantly exceeds industry standards, highlighting the potential of AI in drug discovery 1

1

2

2

. Dr. Michael Hutton, Senior Vice President and CSO of Neurodegeneration and Genetic Medicine at Lilly, praised the Verge team and CONVERGE platform for delivering "scientifically compelling target predictions" supported by "elegant validation experiments in human cell systems" 1

1

.

Lilly's Commitment to ALS Drug Development

As a result of this success, Eli Lilly has opted to pursue the development of therapeutics against two validated drug targets for ALS identified by the CONVERGE platform. This decision has triggered near-term milestone payments from Lilly to Verge, with the potential for additional downstream economics as the programs progress 1

1

2

2

.

Collaboration Details and Financial Implications

The collaboration between Verge and Lilly, established in 2021, is a three-year agreement focused on discovering and validating novel therapeutic targets for ALS. The deal included up to $25 million in upfront payments, equity investment, and potential near-term milestones, with a total deal value of $694 million plus potential downstream royalties 1

1

2

2

.

Verge's Internal ALS Drug Candidate Advances

In addition to the Lilly collaboration, Verge is advancing its internal lead drug candidate, VRG50635, for the treatment of sporadic and familial ALS. The compound is currently undergoing a Phase 1B Proof-of-Concept study in Canada and several European countries 1

1

2

2

. VRG50635 is described as a potent, orally bioavailable, and brain-penetrant PIKfyve inhibitor that has shown promising results in preclinical studies 1

1

.

The CONVERGE Platform: A Game-Changer in Drug Discovery

Verge's proprietary CONVERGE platform represents a significant advancement in the field of drug discovery. By combining human genomics from patient disease tissues with machine learning, the platform has created one of the largest and most comprehensive databases of multi-omic patient data in the field 1

1

2

2

. This approach allows for unique insights into the biological underpinnings of complex diseases like ALS.

Implications for Future Drug Development

The success of the Verge-Lilly collaboration demonstrates the potential of AI-driven approaches in accelerating drug discovery and improving the efficiency of target identification. As the pharmaceutical industry continues to embrace AI and machine learning technologies, partnerships like this may become increasingly common, potentially leading to faster development of treatments for complex diseases with high unmet needs 1

1

2

2

.